American journal of translational research · 2026
Hepatoprotective effects of modified Yiguanjian decoction in pregnant patients with chronic hepatitis B.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wen Ya, Tang Yongyan, Zhang Yu, Zhang Lina, Yao Xiaoying, Xu Qiujin
Аннотация
OBJECTIVE: To investigate the efficacy of modified Yiguanjian decoction (MYGD) as a hepatoprotective treatment for pregnant patients with chronic hepatitis B (CHB).
METHODS: Pregnant patients with CHB hospitalized from October 2022 to December 2024 were enrolled and divided into a MYGD group (n = 88) and a conventional group (n = 83). The efficacy, traditional Chinese medicine (TCM) syndrome scores, liver function indicators (alanine aminotransferase, aspartate aminotransferase, total bilirubin, total bile acids), serum liver fibrosis markers (type III procollagen, type IV procollagen, hyaluronidase, laminin), portal vein diameter, spleen length, spleen thickness, pregnancy-related indicators (uterine artery resistance index (RI), serum estriol (uE3)), and clinical safety were observed and statistically analyzed.
RESULTS: Compared with the conventional group, the MYGD group showed significantly higher efficacy, after treatment (all P < 0.05). The TCM syndrome score was significantly reduced, liver function indicators and serum liver fibrosis markers decreased, portal vein diameter and spleen length shortened, spleen thickness and RI decreased, and uE3 levels increased (all P < 0.05). The clinical safety was comparable between the two groups (P > 0.05).
CONCLUSION: The combined use of MYGD significantly improved the treatment effect in pregnant patients with CHB, and improved symptoms, liver function, and the degree of liver fibrosis, with good safety.
METHODS: Pregnant patients with CHB hospitalized from October 2022 to December 2024 were enrolled and divided into a MYGD group (n = 88) and a conventional group (n = 83). The efficacy, traditional Chinese medicine (TCM) syndrome scores, liver function indicators (alanine aminotransferase, aspartate aminotransferase, total bilirubin, total bile acids), serum liver fibrosis markers (type III procollagen, type IV procollagen, hyaluronidase, laminin), portal vein diameter, spleen length, spleen thickness, pregnancy-related indicators (uterine artery resistance index (RI), serum estriol (uE3)), and clinical safety were observed and statistically analyzed.
RESULTS: Compared with the conventional group, the MYGD group showed significantly higher efficacy, after treatment (all P < 0.05). The TCM syndrome score was significantly reduced, liver function indicators and serum liver fibrosis markers decreased, portal vein diameter and spleen length shortened, spleen thickness and RI decreased, and uE3 levels increased (all P < 0.05). The clinical safety was comparable between the two groups (P > 0.05).
CONCLUSION: The combined use of MYGD significantly improved the treatment effect in pregnant patients with CHB, and improved symptoms, liver function, and the degree of liver fibrosis, with good safety.